Cadrenal Therapeutics Q1 net loss widens to $3.8M; cash at $7.3M; tecarfarin development advances

Cadrenal Therapeutics, Inc.

2025-Q1 EPS reported -$2.09

Net loss of $3.8M for Q1 2025 vs $1.7M in Q1 2024; R&D expense $1.7M (up from $0.6M), G&A $2.3M (up from $1.1M).
Cash and equivalents $7.3M at Mar 31, 2025, down from $10.0M at Dec 31, 2024; 1.9M common shares outstanding.
Appointed Dr. James Ferguson as CMO in February 2025 to lead clinical development and business development.
FDA Type D meeting in Feb 2025 provided guidance for Phase 3 tecarfarin trial; Abbott collaboration announced for TECH-LVAD trial.
Completed API manufacturing transfer from Asia to U.S. CDMO; LVAD market research projects near doubling by 2032.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.